

The human Pluripotent Stem Cell registry

Scientific and ethical qualification of pluripotent stem cells for European research

Andreas Kurtz, Charité











Overview

- Qualification of Pluripotent Stem Cells
- Ethical aspects
- Scientific aspects
- Implementation in hPSCreg











PSC research publications











Risks if no qualification



- Lack of peer review of new (and existing) cell lines
- Widespread use of cell lines without appropriate ethical consent
- Widespread use of cross-contaminated or poorly characterized cell lines causing inheritance of misleading data
- Difficulty in locating appropriate hESC and hiPSC lines with duplication of effort and resultant waste of research funds
- Common use of only a few well characterized lines with potential distorted generalization

CHARITÉ









Ethics Qualification children data Data Animal primates healthy sam Per informed issues countries bloo developing storage nonhuman cells research Ines adult ō abol CHARITÉ Centre de Medicina Regenerativa de Barcelona CMR_B Centro de Medicina Regenerativa de Barcelona UK StemCellBank

Center of Regenerative Medicine in Barcelona





The donor determines what can be done with his or her tissues and the cells derived from these tissues

Issues	
Consent	The donor needs to be informed about all aspects of the planned research and how it affects him or her
Data Protection	The donor needs to be informed about how provacy is protected and misuse of data prevented
Permited Uses	The donor needs to permit possible usage of the cells in research and application
Regulations and Legal aspects	Rules and regulations need to be applied when consenting the donor, protecting the data, using the cells and restrict their use

Centre de Medicina Regenerativa de Barcelona

Centro de Medicina Regenerativa de Barcelon

Center of Regenerative Medicine in Barcelona









Has consent been obtained from the donor of the tissue from which iPS cells have been made?

Was the consent **voluntarily** given by the donor? Do you (Depositor/Provider) hold **a copy of the donor Consent**?

If not, do you know who holds the original donor Consent ? Could you obtain a copy of the signed Consent from the holder? Could you arrange to obtain a new form of Consent, from the donor? Can you provide us with a copy, in English, of the Consent Information provided to the donor?

Can you provide us with a copy, in ist original language, of the Consent Information provided to the donor?

Was the donor informed about how her/his data will be protected?

Has the donated material been coded for traceability or pseudonymised?

Has the donated material been rendered unidentifiable (anonymised)? Has the donor been informed that **participation will not directly influence their personal treatment**?











Permitted Uses: Research

Does Consent pertain to one or more specific research projects?

Does Consent permit unforeseen future research, without further consent?

Is future research permitted only in relation to specified areas or types of research? If so, what are they?

Does the Consent permit uses of donated material intended for clinical treatment or human application?

Does Consent permit research by an academic institution?

Does Consent permit research by a public organisation?

Does Consent permit research by a not-for-profit company?

Does Consent permit research by a for-profit corporation?

Does Consent expressly permit derivation of iPS cells?











Permitted Uses: Commercial Exploitation

Does Consent expressly prevent development of commercial products?

Does the Consent expressly prevent **financial gain** from any use of donated material, including products that might be developed from it?

Storage of and Access to Material

Does Consent expressly permit storage of donated material?

Does Consent expressly permit storage of cells derived from the donated material?

Does the Consent prevent donated material from being made available to researchers anywhere in the world?

Does the Consent prevent cells derived from the donated material from being made available to researchers anywhere in the world?











Benefits

Will the donor expect to receive some financial benefit, beyond reasonable expenses, in return for participation in research?

Does the Consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples, or iPS cells made from them?

Does the consent prevent the donor from receiving **financial benefit** from commercial products, which result from research with the donated material or deived cells?











Data and Information

Does Consent expressly permit collection of genetic information?

Does Consent expressly permit storage of genetic information?

Does the donor Consent prevent dissemination of genetic information?

Was the donor informed that their donation or derived materials may be tested for the presence of microbiological agents and pathogens?

Does the donor expect to be informed by researchers if, during use of donated material, they discover something that has significant health implications for the donor (incidental findings)?

How is genetic information associated with the cell line accessible?

Medical Records

Does Consent permit access to medical records of the donor?

Does consent permit access to any other source of information about the clinical treatment or health of the donor?











Ethical Qualification for EU

Risk anticipation and mitigation

Ex-ante process

- Identifies the issues and risks
- Offers processes/solutions to mitigate them,
- Protects the researcher, the project and the funding bodies,
- Minimizes adverse impact
- Enhances consent

Risk treated as a legal hazard

Ex-post process

- Implies large budget provisions for lawsuits/litigations.
- Internal review processes have NO VALUE in court.
- Risk for researchers of being blocked by third parties – even at publication stage

Risk is inherent to research









Is there evidence of Pluripotency?

Issues	
Phenotype evidence	Expression of 'pluripotency markers' and morphology of the cells
Functional evidence	Differentiate into derivatives of the three germ layers

What is the genetic or disease background of the donor?











	🍪 hES	creg	Q Search SA	002	Browse	i About	My hESCreg	
	General	hESC	Culture C	onditions Char	racterization	Geno	typing	
	Mic	robiology / Virology S	creening	HIV 1: Negative HIV 2: Negative Hepatitis B: Negativ Hepatitis C: Negativ	Edit marker			
			Undiffere	ntiated cells	Select meth	hod Imm	une/Markerstaining	¥
	Mor	phology and Marker e	(pression	Immune/Markersta Passage number: POU5F1 (OCT-4 SSEA-3 SSEA-4 TRA 1-60 TRA 1-81 hES-Cellect SSEA-1	AP staining NANOG POU5F1 (OU SSEA-3 SSEA-4 TRA 1-60 TRA 1-81	mber RT-P FACS Morr Expr	une/Markerstaining CR S phology ession profiles (Omics)	
				RT-PCR:	ZFP42 (REX hES-Cellect	(-1) O		+
				Passage number:	SSEA-1 O			-
www.bosstog.ou/colls/ga	+D-+-2id= 262			Telomerase Activ	Add new (0		



Regenerative Therapies BCRT

Don	or Data/Information
Is there a disease diagnosed?	 yes no Disease Ontology ID - Disease Ontology DOID:11665 get name and synonyms Disease Name: Patau syndrome Synonyms: D1 Trisomy EXACT NCI2004_11_17:C36529 Patau's syndrome RELATED ICD9CM_2006:758.1 trisomy 13 EXACT Open at Disease Ontology
Additional information on disease Q	
Has an abnormal karyotype been diagnosed? 🥥	 yes no Was the abnormal karyotype diagnosed in the donor? yes no Was the abnormal karyotype diagnosed in the cell line? yes no
Are there cell lines registered from the same donor? O	no
Internal donor ID 🛛	
Sex Country of donor origin 🕢	Female ▼ Sweden ▼
CellBank Berlin-Brandenburg Center for Begenerative Therapies BCPT	TÉ CMREB Centre de Medicina Regenerativa de Barcelona Centro de Medicina Regenerativa de Barcelona Centro of Regenerative Medicine in Barcelona



A nomenclature to provide traceability



Unique Donor Identifier











Usage of lines

hESC Line	Year of Publication	Provider	Use in compa- rative reserach (%)	Use in overall research (% of studies)
H9	1998	WiCell	57.4	47.1
H1	1998	WiCell	29.8	24.5
H7	1998	WiCell	7.2	8.0
HES-3	2000	ES Cell International	4.8	6.5
KhES-1	2006	Kyoto University	4.8	3.1
KhES-3	2006	Kyoto University	4.6	2.5
HUES6	2004	Harvard University	4.0	1.7
HUES9	2004	Harvard University	3.8	4.3
BG01	2001	BresaGen	3.5	4.9
HES-2	2000	ES Cell International	2.9	4.5
H14	1998	WiCell	2.9	2.2











	Karyotyping
Karyotyping	🗌 yes 📄 no
CGH	🗌 yes 📄 no
	Genotyping
HLA typing	🗌 yes 📄 no
STR/Fingerprinting	🗌 yes 📄 no
SNP	🗌 yes 📄 no
Microarrays	🗌 yes 📄 no
Sequencing	🗌 yes 📄 no
Other	🗌 yes 📄 no





















	Diseas		Country		Derivation Date	~			
1			Choose a c	country	from	1 May 07			
	Pata	u syndrome (3)							
Ту	Kline	felter's syndrome	\$	Country	Derivation 🗘	Disease 🗘			
hE	(5) Dowi	n syndrome (1)	man ES cell line	Sweden	2001-05-21	Patau syndrome			
hE	SC	Cellartis AB Sweden - H derivation	Human ES cell line	Sweden	2001-09-01	Klinefelter's syndrome			
hE	SC	King's College - Depart Health	ment of Women's	United Kingdom	2007-04-12	Klinefelter's syndrome			











www.hescreg.eu/browse/list_projects	
Provide the search the	Browse <i>i</i> About My hESCreg
DETECTIVE 🖻	1st Jan 2011 - 31st Dec 2015
Detection of endpoints and biomarkers of repeated dose toxi	icity using in vitro systems
SCREENTOX 🖻	1st Jan 2011 - 31st Dec 2015
Stem Cells for Relevant Efficient Extended and Normalized 7	Toxicology
Associated Cell Lines:	
CEBe007-A CEBe010-A CEBe011-A CEBe012-A CEBe014	-A CEBe015-A CEBe016-A CEBe017-A CEBe018-A
CEBe021-A CEBe022-A CEBe023-A CEBe025-A CEBe026	CEBe027-A CEBe028-A CEBe029-A CEBe030-A
CEBe031-A CEBe032-A AXORe003-A AXORe006-A KCLef	001-A KCLe002-A HVRDe001-A HVRDe003-A
(HVRDe007-A) (HVRDe009-A) (WICELLe001-A) (WICELLe003-A) (JNCASRe002-A) (WICELLe003-A-2) (CMFTe001-A) (VUBe001-A-	(CEBe033-A) (CEBe034-A) (JNCASRe001-A)
DDPDGENES 🗠	1st Jan 2012 - 31st Dec 2015
Identification of genes important for human midbrain dopamin	ne neuron development and Parkinson's disease
TISSUEGEN 🗠	1st Jan 2012 - 31st Dec 2015
The production of a 3D human tissue disease platform to ena	able regenerative medicine therapy development
EPIHEALTH 🗠	1st Nov 2011 - 31st Oct 2015











Processing of data



























































Version: 289 (Check Compatability) · Rendering Time: 0.0062





CHARITÉ















Body Browser: Gene expression

Regenerative Therapies BCRT

Human Adult Female Body	Q s	å † ♀	Search		
	GGT1 😒 Heat	Map Modus 😣	adrenal gland	0.4 / 0.5	•
60			brain	0.16 / 0.3	
		ٹ	breast	0.14 / 0.1	
			heart	0.01 / 0.0	
STERS			kidney	1.73 / 81.9	
			large intestine	0.14 / 0.1	
			liver	2.15 / 2.2	11
			lung	0.29 / 0.3	
			ovary	0.35 / 1.7	
			skeletal muscle	0.03 / 0.0	
			thyroid gland	0.5 / 0.6	Ŧ
			Details		
			Heatmap	0 0	3
	ovary 0.35 / 1.7 skeletal muscle 0.03 / 0.0 thyroid gland 0.5 / 0.6 Details Heatmap 0 0 0 0.01 TPM 81.9 Human BodyMap 2.0 CD24 © GGT1 © NPHS1 © PAX2 ©				
			CD24 & GGT1 & NPHS1 & NPHS2 & PAX2 &		
Adrena gland					
CHILD CLIM			Histologic Images		
			Centre de Medicina Regenerativa de Barcelona		

hPSC^{reg}



Summary

- One stop information hub for established, quality controlled human PSC lines
- Validated ethical procurement of lines
- Scientific QC and characterization data for lines
- Enable access to and comparison of cell associated information
- Enable and integrate user feedback / data supplementation









